Raghuram Selvaraju

Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization

Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally

Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug

Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally

Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug

Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit

Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline

Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit

Inovio Analysts Bullish On Prospects For Coronavirus Vaccine, Biotech's Pipeline

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Inovio Analysts Tackle Coronavirus Vaccine Timeline, Funding, Pipeline After Q1 Report

Raghuram Selvaraju Recent News

Inovio Analysts Project About 24% Upside Potential Amid Optimism On Coronavirus DNA Vaccine

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and

Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside

HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies

HTG Molecular's Deal With Merck KGaA 'Provides Further Validation' For EdgeSeq Technology

What You Should Know About The Drug Approval Valeant Could Receive This Week

What's The FDA Saying About Valeant's Manufacturing Facility Issues?

An 'Unsung Potential Winner,' ObsEva Initiated At Buy

FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study

Inovio's HIV Vaccine Elicits High Response Rates In Phase 1 Trial

Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

What Synergy's New Patents Mean For Its Commercial Prospects

Analyst: Synergy Pharma Could Achieve Sustainable Profitability By 2018

More Than 100% Upside Seen In Imprimis After Q4 Results

Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable

Synergy Pharma's Plecanitide Finally Crosses The Finish Line; Rodman & Renshaw Lifts Price Target To $18

Synergy Hits Endpoints, Earns A Price Target Bump At Rodman & Renshaw

With Valeant's Continued Deterioration, Rodman & Renshaw Downgrades To Neutral

Rodman & Renshaw Prescribe A $6 Price Target For Cancer Genetics

Sum-Of-The-Parts Valuation Leads Rodman & Renshaw To Initiate Oasmia Pharmaceuticals At Buy With A $6 Target

Inovio Initiates Second Zika Vaccine Human Trial; Wainwright Reiterates Buy Rating